Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies by Richard Burt, Dana Warcel, Adele K. Fielding

Connect to this object online.

Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity by Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Sam Salek

Connect to this object online.

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study by Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek

Connect to this object online.

Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO by Pushpendra Goswami, Esther N. Oliva, Tatyana Ionova, Roger Else, Jonathan Kell, Adele K. Fielding, Daniel M. Jennings, Marina Karakantza, Saad Al-Ismail, Graham P. Collins, Stewart McConnell, Catherine Langton, Magda J. Al-Obaidi, Metod Oblak, Sam Salek

Connect to this object online.